Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("RAZOXANE")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 144

  • Page / 6

Export

Selection :

  • and

Razoxane: a review of 6 years' therapy in psoriasisHORTON, J. J; WELLS, R. S.British journal of dermatology (1951). 1983, Vol 109, Num 6, pp 669-673, issn 0007-0963Article

BIOLOGICAL PROPERTIES OF ICRF-159 AND RELATED BIS(DIOXOPIPERAZINE) COMPOUNDSHERMAN EH; WITIAK DT; HELLMANN K et al.1982; ADV. PHARMACOL. CHEMOTHER.; ISSN 0065-3144; USA; DA. 1982; VOL. 19; PP. 249-290; BIBL. 5 P.Article

Radiotherapy and razoxane in advanced bile duct carcinomasRHOMBERG, Walter; STEPHAN, Hans; BÖHLER, Franz et al.Anticancer research. 2005, Vol 25, Num 5, pp 3613-3618, issn 0250-7005, 6 p.Article

Treatment options for malignant hemangioendotheliomas of the thyroidRHOMBERG, Walter; BOEHLER, Franz; EITER, Helmut et al.International journal of radiation oncology, biology, physics. 2004, Vol 60, Num 2, pp 401-405, issn 0360-3016, 5 p.Article

BIS-DIKETOPIPERAZINE DERIVATIVES IN CLINICAL ONCOLOGY: ICRF-159POSTER DS; PENTA J; MARSONI S et al.1980; CANCER CLIN. TRIALS; ISSN 0190-1206; USA; DA. 1980; VOL. 3; NO 4; PP. 315-320; BIBL. 35 REF.Article

UTILIZATION OF AN ENANTIOMER AS A SOLUTION TO A PHARMACEUTICAL PROBLEM: APPLICATION TO SOLUBILIZATION OF 1,2-DI(4-PIPERAZINE-2,6-DIONE) PROPANEREPTA AJ; BALTEZOR MJ; BANSAL PC et al.1976; J. PHARM. SCI.; U.S.A.; DA. 1976; VOL. 65; NO 2; PP. 238-242; BIBL. 30 REF.Article

Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomasRHOMBERG, Walter; EITER, Helmut; BÖHLER, Franz et al.Anticancer research. 2006, Vol 26, Num 3B, pp 2407-2411, issn 0250-7005, 5 p.Article

THE INFLUENCE OF ICRF-159 AND LEVAMISOLE ON THE INCIDENCE OF METASTASES FOLLOWING LOCAL IRRADIATION OF A SOLID TUMORBAKER D; CONSTABLE W; ELKON D et al.1981; CANCER; ISSN 0008-543X; USA; DA. 1981; VOL. 48; NO 10; PP. 2179-2183; BIBL. 32 REF.Article

Razoxane and vindesine in advanced soft tissue sarcomas : Impact on metastasis, survival and radiation responseRHOMBERG, Walter; EITER, Helmut; SCHMID, Franz et al.Anticancer research. 2007, Vol 27, Num 5B, pp 3609-3614, issn 0250-7005, 6 p.Article

Combined razoxane and radiotherapy for melanoma brain metastases. A retrospective analysisRHOMBERG, Walter; EITER, Helmut; BOEHLER, Franz et al.Journal of neuro-oncology. 2005, Vol 74, Num 3, pp 295-299, issn 0167-594X, 5 p.Article

RAZOXANE REGIMEN FOR THE TREATMENT OF PSORIASISHARPER JI; COPEMAN PWM; STAUGHTON RCD et al.1982; CLIN. EXP. DERMATOL.; ISSN 0307-6938; GBR; DA. 1982; VOL. 7; NO 2; PP. 217-218; BIBL. 1 REF.Article

Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxaneANDERSON, H; YAP, J. T; WELLS, P et al.British journal of cancer. 2003, Vol 89, Num 2, pp 262-267, issn 0007-0920, 6 p.Article

TREATMENT OF KAPOSI'S SARCOMA WITH ICRF-159 (NSC-129943)OLWENY CLM; MASABA JP; SIKYEWUNDA W et al.1976; CANCER TREATM. REP.; U.S.A.; DA. 1976; VOL. 60; NO 1; PP. 111-113; BIBL. 7 REF.Article

REDUCTION OF DAUNOMYCIN TOXICITY BY RAZOXANEWANG G; FINCH MD; TREVAN D et al.1981; BR. J. CANCER; ISSN 0007-0920; GBR; DA. 1981; VOL. 43; NO 6; PP. 871-877; BIBL. 5 REF.Article

RANDOMIZED CLINICAL TRIAL COMPARING TWO DOSE REGIMENS OF ICRF-159 IN REFRACTORY MALIGNANT LYMPHOMASO'CONNELL MJ; BEGG CB; SILVERSTEIN MN et al.1980; CANCER TREAT. REP.; ISSN 0361-5960; USA; DA. 1980; VOL. 64; NO 12; PP. 1355-1358; BIBL. 4 REF.Article

ICRF 159-INDUCED CELL CYCLE PERTURBATION IN VITRO: ITS RELATIONSHIP TO INHIBITION OF COLONY-FORMING ABILITYEDGAR DH; CREIGHTON AM.1981; BR. J. CANCER; ISSN 0007-0920; GBR; DA. 1981; VOL. 44; NO 2; PP. 236-240; BIBL. 14 REF.Article

ICRF-159 (RAZOXANE) IN THE TREATMENT OF PEDIATRIC SOLID TUMORS: A SOUTHWEST ONCOLOGY GROUP STUDYDYMENT PG; STARLING KA; LAND VJ et al.1979; CANCER TREATM. REP.; USA; DA. 1979; VOL. 63; NO 8; PP. 1397-1398; BIBL. 6 REF.Article

RAZOXANE: A NEW ANTI-TUMOUR AGENT.1978; DRUG THERAPEUT. BULL.; G.B.; DA. 1978; VOL. 16; NO 2; PP. 7-8; BIBL. 17 REF.Article

RAZOXANEATHERTON DJ.1981; CLIN. EXP. DERMATOL.; ISSN 0307-6938; GBR; DA. 1981; VOL. 6; NO 6; PP. 647-650; BIBL. 12 REF.Article

RAZOXANE (ICRF 159) IN THE TREATMENT OF PSORIASISATHERTON DJ; WELLS RS; LAURENT MR et al.1980; BRIT. J. DERMATOL.; GBR; DA. 1980; VOL. 102; NO 3; PP. 307-317; BIBL. 16 REF.Article

HYPOXIC CELL RADIOSENSITIZERS AND LOCAL CONTROL BY X-RAY OF A TRANSPLANTED TUMOUR IN MICE.SHELDON PW; HILL SA.1977; BRIT. J. CANCER; G.B.; DA. 1977; VOL. 35; NO 6; PP. 795-808; BIBL. 1 P. 1/2Article

TREATMENT OF BLAST CELL CRISIS OF CHRONIC MYELOID LEUKEMIA WITH ICRF-159 (RAZOXANE)BAKOWSKI MT; BREARLEY RL; WRIGLEY PFM et al.1979; CANCER TREATM. REP.; USA; DA. 1979; VOL. 63; NO 11-12; PP. 2085-2087; BIBL. 6 REF.Article

METAL BINDING BY PHARMACEUTICALS. II: INTERACTIONS OF CA(II), CU(II), FE(II), MG(II), MN(II) AND ZN(II) WITH THE INTRACELLULAR HYDROLYSIS PRODUCTS OF THE ANTITUMOUR AGENT ICRF 159 AND ITS INACTIVE HOMOLOGUE ICRF 192ZHONG XIAN HUANG; MAY PM; QUINLAN KM et al.1982; AGENTS AND ACTIONS; ISSN 0538-4818; CHE; DA. 1982; VOL. 12; NO 4; PP. 536-542; BIBL. 32 REF.Article

RAZOXANE REGIMEN FOR THE TREATMENT OF PSORIASISHARPER JI; COPEMAN PWM; STAUGHTON RCD et al.1982; CLIN. EXP. DERMATOL.; ISSN 0307-6938; GBR; DA. 1982; VOL. 7; NO 5; PP. 581-582; BIBL. 1 REF.Article

A CONTROLLED PROSPECTIVE TRIAL OF ADJUVANT RAZOXANE IN RESPECTABLE COLORECTAL CANCERGILBERT JM; CASSELL PC; ELLIS H et al.1981; RECENT RESULTS CANCER RES.; ISSN 0080-0015; USA; DA. 1981; VOL. 79; PP. 48-58; BIBL. 15 REF.Conference Paper

  • Page / 6